tiprankstipranks
Company Announcements

Cellebrite Achieves Strong 2024 Financial Performance with Significant ARR Growth

Story Highlights
  • Cellebrite achieved 25% ARR growth and a 25% adjusted EBITDA margin in 2024.
  • Cellebrite expects continued growth in 2025, supported by strategic advancements and leadership changes.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cellebrite Achieves Strong 2024 Financial Performance with Significant ARR Growth

Discover the Best Stocks and Maximize Your Portfolio:

The latest update is out from Cellebrite DI ( (CLBT) ).

Cellebrite reported strong financial results for 2024, achieving a significant 25% growth in annual recurring revenue (ARR) and maintaining a 25% adjusted EBITDA margin, signaling a ‘Rule of 50’ performance. The company experienced a 17% increase in fourth-quarter revenue, driven by a 21% rise in subscription revenue, while also achieving important milestones such as the FedRAMP High Ready designation for its Government Cloud platform. The firm announced leadership changes and strategic advancements, positioning it for sustained growth and profitability in 2025, with expectations of continued top-line expansion and robust free cash flow.

More about Cellebrite DI

Cellebrite DI Ltd. is a global leader in digital investigative solutions serving both the public and private sectors. The company specializes in providing advanced technology solutions to uncover digital evidence for criminal investigations, with a strong market focus on expanding its digital and cloud-based offerings.

YTD Price Performance: 15.05%

Average Trading Volume: 1,523,262

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $5.19B

See more data about CLBT stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1